ReviewJournal of the National Cancer Institute2022
Grade Migration of Prostate Cancer in the United States During the Last Decade.
Review in Journal of the National Cancer Institute, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted and Systematic Prostate Biopsy to Prevent Infectious Complications: The PREVENT Randomized Trial.European urology · 2024Trial
- Prostate-Specific Antigen Screening Patterns and Metastatic Prostate Cancer in US Veterans.JAMA network open · 2026Article
- LINC00222 regulates FOXO3 to interfere with β-catenin signaling pathway and suppresses prostate cancer progression.Scientific reports · 2026Article
- Incidence of High-Risk Prostate Cancer in Korea: Insights From Real-World Data Between 2010 and 2020.Journal of Korean medical science · 2026Article
- Screening policy changes and prostate cancer epidemiology: 20-year trends in diagnosis, treatment, incidence, and mortality.World journal of urology · 2026Article
- Trends of upgrading and upstaging of grade group 1 prostate cancer at radical prostatectomy: NCDB and SEER results from 2010 to 2021.Current urology · 2025Article
- Association between neutrophil percentage-to-albumin ratio and prostate cancer: A cross-sectional study.Medicine · 2025Article
- Using Machine Learning to Create Prognostic Systems for Primary Prostate Cancer.Diagnostics (Basel, Switzerland) · 2025Article
- Spatially organized lymphocytic microenvironments in high grade primary prostate tumors.bioRxiv : the preprint server for biology · 2025Article
- Biomarkers for Prostate Cancer Aggressiveness in Puerto Rican Men: Analysis of Phospho-Rb S249, N-cadherin, β-catenin, and E-cadherin Expression in Prostate Biopsies.Ponce Health Sciences University scientific journal · 2025Article
- Real-World Management of High-Risk Prostate Cancer Post-Radical Prostatectomy: Insights from a Regional Quality Collaborative.Cancers · 2025Article
- Advances in Current Treatment Paradigms for Metastatic Hormone-Sensitive Prostate Cancer.Journal of clinical medicine · 2025Review
- Cancer awareness across borders: a comparative study of internet search trends for breast and prostate cancer in Europe and Turkey.BMC cancer · 2024Article
- A Ten Year Experience of Men's Health Events in a Socioeconomically Diverse City in the United States - Lessons Learned.Journal of community health · 2024Article
- Identification of a 5-gene signature panel for the prediction of prostate cancer progression.British journal of cancer · 2024Article
- Trends in age and prostate-specific antigen at prostate cancer diagnosis between 2010 and 2019.JNCI cancer spectrum · 2024Article
- Associations of systemic immune-inflammation index with high risk for prostate cancer in middle-aged and older US males: A population-based study.Immunity, inflammation and disease · 2024Article
- Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer.JAMA oncology · 2024Article
- Observational
- Racial Disparities in Clinical Trial Enrollment Among Patients Diagnosed With Prostate Cancer: A Population-Based Cohort of Oncology Practices.Advances in urology · 2024Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
10 authors.
Funding
Abstract
backgroundProstate cancer (PC) screening guidelines have changed over the last decade to reduce overdiagnosis and overtreatment of low-grade disease. We sought to examine and attempt to explain how changes in screening strategies have impacted temporal trends in Gleason grade group (GG) PC at diagnosis and radical prostatectomy pathology.
methodsUsing the Surveillance, Epidemiology, and End Results Registry database, we identified 438 432 men with newly diagnosed PC during 2010-2018. Temporal trends in incidence of GG at biopsy, radical prostatectomy pathology, prostate-specific antigen (PSA) level, and metastasis at diagnosis were examined. The National Health Interview Survey database was examined to evaluate trends in PSA-screening rates, and a literature review evaluating magnetic resonance imaging and biomarkers utilization during this period was performed.
resultsBetween 2010 and 2018, the incidence of low-grade PC (GG1) decreased from 52 to 26 cases per 100 000 (P < .001). The incidence of GG1 as a proportion of all PC decreased from 47% to 32%, and the proportion of GG1 at radical prostatectomy pathology decreased from 32% to 10% (P < .001). However, metastases at diagnosis increased from 3.0% to 5.2% (P < .001). During 2010-2013, PSA screening rates in men aged 50-74 years declined from 39 to 32 per 100 men and remained stable. Utilization rates of magnetic resonance imaging and biomarkers modestly increased from 7.2% in 2012 to 17% in 2019 and 1.3% in 2012 to 13% in 2019, respectively.
conclusionsWe found a significant decrease in the diagnosis and treatment of GG1 PC between 2010 and 2018. Changes in PSA screening practices appear as the primary contributor. Public health efforts should be directed toward addressing the increase in the diagnoses of metastatic PC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.